orphan drug designation - Robuta Search

https://www.verahealth.ai/ja/news/pemphigus-vulgaris-resecabtagene-autoleucel-receives-fda-orphan-drug-designation Pemphigus vulgaris: resecabtagene autoleucel receives FDA orphan drug designation - Vera Health ニュース FDA OOPD listing shows designation granted March 14, 2026 for pemphigus vulgaris, signaling regulatory momentum for a cell therapy approach but no orphan... orphan drug designation pemphigus vulgaris receives fda vera https://www.fshdsociety.org/fr/2023/02/16/avidity-gets-orphan-drug-designation/ Avidity gets orphan drug designation - FSHD Society Feb 16, 2023 - Avidity Biosciences announced this week that it had received FDA Orphan Drug Designation for its experimental FSHD treatment, called AOC 1020. This does NOT... orphan drug designation avidity gets fshd society https://healthnewswire.com/press-release/neuroene-therapeutics-announces-orphan-drug-designation-granted-by-fda-for-dravet-syndrome-treatment-nt102-301411587/ Neuroene Therapeutics Announces Orphan Drug Designation Granted by FDA for Dravet Syndrome... CHARLESTON, S.C., Oct. 29, 2021 /PRNewswire/ — Neuroene Therapeutics announced that the FDA has granted orphan drug designation for the orphan drug designation dravet syndrome therapeutics announces granted https://psynews.com/pharmadrug-announces-first-fda-orphan-drug-designation-of-dmt-for-the-prevention-of-ischemia-reperfusion-injury-from-organ-transplantation/ PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of... Toronto, Ontario–(Newsfile Corp. – April 28, 2021) – PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“ PharmaDrug” or the “Company“), a specialty pharmaceutical... orphan drug designation for the announces first fda https://coyatherapeutics.com/coya-therapeutics-receives-orphan-drug-designation-from-the-fda-for-als001-an-autologus-treg-cell-therapy-for-the-treatment-of-als/ Coya Therapeutics Receives Orphan Drug Designation from the FDA for ALS001, an Autologus Treg Cell... Sep 28, 2022 - Completed Phase 2a trial with full data release by end of summer 2021 HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) — Coya Therapeutics, Inc. (Coya), a... orphan drug designation from the treg cell coya therapeutics https://www.geneonline.com/fda-grants-orphan-drug-designation-to-fs2-for-potential-treatment-of-idiopathic-pulmonary-fibrosis/ FDA Grants Orphan Drug Designation to FS2 for Potential Treatment of Idiopathic Pulmonary Fibrosis... Dec 2, 2025 - The U.S. Food and Drug Administration (FDA) has granted […] orphan drug designation idiopathic pulmonary fibrosis fda grants potential https://www.khondrion.com/news/khondrion-granted-orphan-drug-designation-for-kh176-for-the-treatment-of-midd-from-european-commission Khondrion | Khondrion granted Orphan Drug Designation for KH176 for the treatment of MIDD from... Khondrion granted Orphan Drug Designation for KH176 for the treatment of maternally inherited diabetes and deafness (MIDD) from European Commission... orphan drug designation the treatment granted midd https://healthcarejournaloregon.com/article/854568470-aavantgarde-announces-fda-orphan-drug-designation-and-uk-cta-approval-for-aavb-039-for-the-treatment-of-stargardt-disease AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the... orphan drug designation announces fda cta approval https://www.pressrelease.com/news/nx-development-corp-is-granted-orphan-drug-designation-status-by-us-22260331 NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan® in Ovarian... orphan drug designation us fda development corp granted https://www.cancernetwork.com/view/atg-022-receives-fda-orphan-drug-designation-for-gastric-pancreatic-cancers ATG-022 Receives FDA Orphan Drug Designation for Gastric/Pancreatic Cancers | CancerNetwork Oct 8, 2026 - Claudin 18.2–targeting antibody-drug conjugate ATG-022 is under assessment as part of the phase 1 CLINCH study in patients with advanced or metastatic solid... orphan drug designation pancreatic cancers atg receives fda https://www.ithanet.eu/latest-information/news/imara-receives-orphan-drug-designation-for-imr-687-for-treatment-of-beta-thalassemia Imara Receives Orphan Drug Designation for IMR-687 for Treatment of β-Thalassemia orphan drug designation imara receives imr treatment https://www.partnertx.com/zenocutuzumab%E2%80%91zbco-receives-fda-orphan-drug-designation-for-treatment-of-cholangiocarcinoma/ Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma –... Designation strengthens BIZENGRI® development program in rare cholangiocarcinoma LEXINGTON, Mass. —February 5, 2026—Partner Therapeutics, orphan drug designation receives fda treatment cholangiocarcinoma https://forbion.com/dk/news-insights/news/azafaros-receives-fda-orphan-drug-designation-for-az-3102-in-gm2-gangliosidosis/ Azafaros Receives FDA Orphan Drug Designation | Forbion Azafaros B.V. today announced that the FDA has granted Orphan Drug Designation (ODD) for AZ-3102, a novel oral small molecule. orphan drug designation receives fda https://www.pharmasalmanac.com/articles/pliant-therapeutics-receives-fda-orphan-drug-designation-for-lead-program-pln-74809-in-idiopathic-pulmonary-fibrosis Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic... Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis orphan drug designation pliant therapeutics receives fda https://www.mabwell.com/en/news_info/id-132.html FDA Grants Orphan Drug Designation to 9MW3011 Mabwell is an innovation-driven biopharmaceutical company with end-to-end capabilities from drug discovery to commercialization. We are committed to provide... orphan drug designation fda grants https://www.globenewswire.com/news-release/2020/10/20/2110917/0/en/Pharmather-Files-for-FDA-Orphan-Drug-Designation-for-Ketamine-in-Parkinson-s-Disease.html Pharmather Files for FDA Orphan Drug Designation for TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”)... orphan drug designation files fda https://targedbiopharmaceuticals.com/news/tgd001-receives-orphan-drug-designation-in-europe/ TGD001 receives Orphan Drug Designation in Europe - TargED Oct 31, 2024 - TargED Biopharmaceuticals is thrilled to announce that the European Medicines Agency has granted Orphan Drug Designation for their innovative therapy, TGD001!... orphan drug designation in europe receives targed https://www.biopharmaboardroom.com/news/11/1550/cabaletta-bios-caba-201-receives-fda-orphan-drug-designation-for-myositis.html Cabaletta Bio's CABA-201 Receives FDA Orphan Drug Designation for Myositis Cabaletta Bio's CABA-201 Receives FDA Orphan Drug Designation for Myositis orphan drug designation cabaletta bio receives fda https://www.partnertx.com/partner-therapeutics-receives-orphan-drug-designation-for-leukine-sargramostim/ Partner Therapeutics Receives Orphan Drug Designation for Leukine® (sargramostim) – Partner... LEXINGTON, Mass., Sept. 19, 2019 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the orphan drug designation partner therapeutics receives sargramostim https://www.pharmtech.com/view/ionis-pharmaceuticals-receives-orphan-drug-designation-httrx Ionis Pharmaceuticals Receives Orphan Drug Designation for HTTRx | Pharmaceutical Technology Oct 8, 2026 - Ionis Pharmaceuticals receives orphan drug designation for HTTRx for the treatment of Huntington’s disease. orphan drug designation ionis pharmaceuticals receives technology https://www.ferapharma.com/pressrelease/fera-obtains-orphan-drug-designation-for-naproxcinod-for-the-treatment-of-sickle-cell-disease/ Fera Obtains Orphan Drug Designation for Naproxcinod for the Treatment of Sickle Cell Disease –... orphan drug designation sickle cell disease the treatment fera obtains https://certatherapeutics.com/certa-therapeutics-ft011-granted-us-fda-orphan-drug-designation-for-the-treatment-of-systemic-sclerosis/ Certa Therapeutics’ FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic... orphan drug designation us fda for the certa granted https://adalta.com.au/adalta-receives-orphan-designation-lead-drug-candidate-targeting-patients-idiopathic-pulmonary-disease/ AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic... Jan 18, 2017 - MELBOURNE Australia, 18 January, 2017 – AdAlta Limited (ASX: 1AD), today announced it has received Orphan Drug Designation from the United States Food and Drug... orphan designation drug candidate receives lead targeting https://pharmaceutical-business-review.com/news/timbers-tmb-001-ec-xlri/ Timber’s TMB-001 receives orphan drug designation from EC to treat XLRI Mar 2, 2023 - Timber Pharmaceuticals has received orphan drug designation from the European Commission (EC) for TMB-001 to treat X-linked recessive ichthyosis (XLRI). orphan drug designation tmb receives treat xlri https://www.legislation.gov.au/C2016G00286/asmade/downloads Designation of Chenodeoxycholic acid as an orphan drug by Link Healthcare - Federal Register of... chenodeoxycholic acid orphan drug federal register designation healthcare https://www.biospace.com/avidity-biosciences-receives-fda-orphan-drug-designation-for-aoc-1044-for-treatment-of-duchenne-muscular-dystrophy-in-people-with-mutations-amenable-to-exon-44-skipping Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne... Aug 15, 2023 - Avidity Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1044, the company's... orphan drug designation avidity biosciences receives fda